


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application

**Listing of Claims:**

1. (Currently Amended) A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a substance selected from a compound represented by the following general formula (I), a pharmacologically acceptable salt thereof, a hydrate thereof, and a solvate thereof:



wherein one of R<sup>1</sup> and R<sup>2</sup> represents hydrogen atom and the other represents the formula —X—A wherein A represents a hydrogen atom, a hydrocarbon-carbonyl group, or an acyl group, a hydrocarbon-sulfonyl group, X represents ~~oxygen~~ an oxygen atom or NH; one of R<sup>3</sup> and R<sup>4</sup> represents hydrogen atom and the other represents the following formula:



wherein

Y represents a sulfonyl group or a carbonyl group,

R<sup>5</sup> represents

a phenyl group which may be substituted with one or more substituents selected from

a halogen atom,

a nitro group,

an alkyl group,

a halogenated alkyl group,

a hydroxyl group,

an alkoxy group,

an alkylenedioxy group,

an amino group,

an N,N-di(alkyl)-amino group, and

an alkyl-sulfonyl group,

a naphthyl group which may be substituted,

a furyl group which may be substituted,

a pyridyl group which may be substituted,

a benzimidazolyl group which may be substituted, or


a cycloalkyl group,

Z represents a single bond or a C<sub>1</sub> to C<sub>4</sub> alkylene group,

R<sup>6</sup> represents hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group,

with the following provisos:

a compound represented by the following formula:



wherein each of A, Z, R<sup>5</sup> and R<sup>6</sup> has the same meaning as that defined above is excluded; when R<sup>3</sup> is hydrogen atom, then Y is a sulfonyl group one of R<sup>1</sup> and R<sup>2</sup> is the formula —O—A, A is a hydrogen atom, Y is a carbonyl group, Z is a single bond, and R<sup>6</sup> is hydrogen atom, then R<sup>5</sup> is

a phenyl group which may be substituted with one or more substituents selected from

a halogen atom,

a nitro group,

an alkyl group,

a halogenated alkyl group,

an alkoxy group,

an alkenedioxy group,

an amino group,

an N,N-di(alkyl)-amino group, and

an alkyl-sulfonyl group,

a naphthyl group which may be substituted,

a furyl group which may be substituted,

a pyridyl group which may be substituted,

a benzimidazolyl group which may be substituted, or

a cycloalkyl group;

when R<sup>2</sup> is the formula —NH—A, A is a hydrogen atom, R<sup>4</sup> is a hydrogen atom, and Y is a sulfonyl group, Z is a C<sub>1</sub> alkylene group, and R<sup>6</sup> is hydrogen atom, then R<sup>5</sup> is

a phenyl group which is substituted with one or more substituents selected from

a halogen atom,

a nitro group,

an alkyl group,

a halogenated alkyl group,

a hydroxyl group,

an alkoxy group,

an alkylenedioxy group,

an amino group,

an N,N-di(alkyl)-amino group, and

an alkyl-sulfonyl group,

a naphthyl group which may be substituted,

a furyl group which may be substituted,

a pyridyl group which may be substituted, ~~or~~

a benzimidazolyl group which may be substituted, or

a cycloalkyl group; and

when R<sup>1</sup> is the formula -NH-A, A is a hydrogen atom, R<sup>2</sup> is a hydrogen atom, Y is a sulfonyl group, Z is a C<sub>1</sub> alkylene group, and R<sup>6</sup> is hydrogen atom, then R<sup>5</sup> is

a phenyl group which is substituted with one or more substituents selected from

a halogen atom,

a nitro group,

an alkyl group,

a halogenated alkyl group,

a hydroxyl group,

an alkoxy group,

an alkylenedioxy group,

an amino group,

an N,N-di(alkyl)-amino group, and

an alkyl-sulfonyl group,

a naphthyl group which may be substituted,

a furyl group which may be substituted,

a pyridyl group which may be substituted,

a benzimidazolyl group which may be substituted, or

a cycloalkyl group; and

when one of R<sup>1</sup> and R<sup>2</sup> is the formula -NH-A, A is a hydrogen atom, Y is a sulfonyl group, Z is a single bond, and R<sup>6</sup> is hydrogen atom, then R<sup>5</sup> is

a phenyl group which may be substituted with one or more substituents selected from

a halogen atom,

a nitro group,

an alkyl group,

a halogenated alkyl group,

a hydroxyl group,

an alkoxy group,

an alkylenedioxy group,

an amino group,

an N,N-di(alkyl)-amino group, and

an alkyl-sulfonyl group,


a naphthyl group which may be substituted,

a furyl group which may be substituted,

a pyridyl group which may be substituted, or

a benzimidazolyl group which may be substituted

compounds of the following formulas are excluded:



2. (Canceled)

3. (Currently Amended) The medicament according to claim 1, wherein Z is a methylene group, an ethylene group, an ethane-1,1-diyl group, a propane-1,3-diyl group, a propane-1,2-diyl group, a propane-2,2-diyl group, or a butane-1,4-diyl group.

4. (Previously Presented) The medicament according to claim 1, wherein Y is a sulfonyl group.

5. (Currently Amended) The medicament according to claim 1, wherein R<sup>1</sup> is a group represented by the formula  $-X-A$  wherein A represents a hydrogen atom, a

hydrocarbon-carbonyl group, or an acyl group a hydrocarbon-sulfonyl group, X  
represents an oxygen atom or NH, and R<sup>2</sup> is a hydrogen atom.


6. (Previously Presented) The medicament according to claim 1, wherein the cancer therapy based on the mode of action of DNA injury is carried out by an administration of an anticancer agent and/or radiation.

7. (Previously Presented) The medicament according to claim 6, wherein the anticancer agent is selected from bleomycin, adriamycin, cisplatin, cyclophosphamide, mitomycin C, and derivatives thereof.

8. (Previously Presented) The medicament according to claim 1, which is a specific inhibitor of a protein kinase and/or an analogous enzyme thereof.

9. (Previously Presented) A medicament for reducing a side effect resulting from a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the general formula (I), a pharmacologically acceptable salt thereof, a hydrate thereof, or a solvate thereof according to claim 1.

10. (Previously Amended) A compound represented by the general formula (I), a pharmacologically acceptable salt thereof, a hydrate thereof, or a solvate thereof according to claim 1, provided that the following compound is excluded:



11. (Previously Presented) A compound selected from the following compounds or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof:

N-Benzyl-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-(2,6-Difluorobenzyl)-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-(2,4-Dichlorobenzyl)-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-(3-Nitrobenzyl)-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-(4-Nitrobenzyl)-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-(2-Methylbenzyl)-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-[4-(tert-Butyl)benzyl]-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-[2-(Trifluoromethyl)benzyl]-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-[4-(Trifluoromethyl)benzyl]-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-(3,4-Dihydroxybenzyl)-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-(2-Methoxybenzyl)-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-(3-Methoxybenzyl)-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide};

N-(2,3-Dimethoxybenzyl)-5-{{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-



sulfonamide;

N-(3,5-Dimethoxybenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-(3,4-Methylenedioxybenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-(3-Aminobenzyl)-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-[4-(Dimethylamino)benzyl]-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-Cyclohexylmethyl-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-Phenyl-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-{{(4-methylphenyl)sulfonyl}oxy}naphthalene-1-sulfonamide;

N-Benzyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(4-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Methylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[2-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,4-Dihydroxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,5-Dimethoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,4-Methylenedioxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Aminobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Dimethylamino)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Methanesulfonyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[(Benzimidazol-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-Cyclohexylmethyl-5-hydroxynaphthalene-1-sulfonamide;  
N-Phenyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(1-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-Benzyl-N-methyl-5-hydroxynaphthalene-1-sulfonamide;  
5-Acetyloxy-N-benzyl naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2,4-dichlorobenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(3-nitrobenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[4-(trifluoromethyl)benzyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(3-aminobenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(1-naphthylmethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[(5-methylfuran-2-yl)methyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[(pyridin-2-yl)methyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(cyclohexylmethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-phenyl naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2-phenethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(1-phenethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
N-Benzyl-5-hydroxynaphthalene-2-sulfonamide;  
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;

N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(3-Aminobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-(Cyclohexylmethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-Phenyl-5-hydroxynaphthalene-2-sulfonamide;  
N-(2-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(1-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-Benzyl-N-methyl-5-hydroxynaphthalene-2-sulfonamide;  
5-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;  
5-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Acetylamino-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Amino-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;  
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;  
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;  
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;  
6-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;  
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

6-Amino-N-benzyl-naphthalene-2-sulfonamide;

6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Amino-N-benzyl-naphthalene-1-carboxamide;

5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-carboxamide; and

5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-carboxamide.

12. (Currently Amended) A medicament which comprises as an active ingredient a substance selected from a compound represented by the general formula (I), a pharmacologically acceptable salt thereof, a hydrate thereof, and a solvate thereof according to claim 10.

13. (Original) A medicament according to claim 12, which is used for enhancing an effect of a cancer therapy based on a mode of action of DNA injury.

14.-16. (Canceled)

17. (Currently Amended) The medicament according to claim [[2]] 1, wherein R<sup>5</sup> is a substituted phenyl group.

18. (Currently Amended) The medicament according to claim [[2]] 1, wherein the compound is selected from the following compounds:

N-Benzyl-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(2,6-Difluorobenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(2,4-Dichlorobenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(3-Nitrobenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(4-Nitrobenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(2-Methylbenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-[4-(tert-Butyl)benzyl]-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-[2-(Trifluoromethyl)benzyl]-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-[4-(Trifluoromethyl)benzyl]-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(3,4-Dihydroxybenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(2-Methoxybenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(3-Methoxybenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(2,3-Dimethoxybenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(3,5-Dimethoxybenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(3,4-Methylenedioxybenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-(3-Aminobenzyl)-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-[4-(Dimethylamino)benzyl]-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-

sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Cyclohexylmethyl-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Phenyl-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Benzyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Methylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[2-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,4-Dihydroxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,5-Dimethoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,4-Methylenedioxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Aminobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Dimethylamino)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Methanesulfonyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[(Benzimidazol-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-Cyclohexylmethyl-5-hydroxynaphthalene-1-sulfonamide;  
N-Phenyl-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(1-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-Benzyl-N-methyl-5-hydroxynaphthalene-1-sulfonamide;  
5-Acetyloxy-N-benzyl-naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2,4-dichlorobenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(3-nitrobenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;



5-Acetyloxy-N-[4-(trifluoromethyl)benzyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(3-aminobenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(1-naphthylmethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[(5-methylfuran-2-yl)methyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[(pyridin-2-yl)methyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(cyclohexylmethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-phenylnaphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2-phenethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(1-phenethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
N-Benzyl-5-hydroxynaphthalene-2-sulfonamide;  
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(3-Aminobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-(Cyclohexylmethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-Phenyl-5-hydroxynaphthalene-2-sulfonamide;

N-(2-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(1-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-Benzyl-N-methyl-5-hydroxynaphthalene-2-sulfonamide;  
5-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;  
5-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Acetylamino-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Amino-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;  
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;  
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;  
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;  
6-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;  
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
6-Amino-N-benzyl-naphthalene-2-sulfonamide;  
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Amino-N-benzyl-naphthalene-1-carboxamide;  
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-carboxamide; and  
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-carboxamide.

19. (Currently Amended) The medicament according to claim [[2]] 1, wherein the compound is N-[4-(tert-butyl)benzyl]-5-[[[4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide.

20. (Withdrawn-Currently Amended) A method for enhancing an effect of a cancer therapy based on a mode of action of DNA injury in a mammal including a human, which comprises applying a cancer therapy based on the mode of action of DNA injury to a cancer patient, and administering a substance selected from ~~of~~ a compound represented by the general formula (I), a pharmacologically acceptable salt thereof, a hydrate thereof, and a solvate thereof according to claim 1, at a dose sufficient to enhance an effect of a cancer therapy.

21. (Withdrawn) The method according to claim 20, wherein R<sup>5</sup> is a phenyl group which may be substituted, a naphthyl group which may be substituted, a furyl group which may be substituted, a pyridyl group which may be substituted, or a benzimidazolyl group which may be substituted.

22. (Withdrawn) A method for reducing a side effect resulting from a cancer therapy based on the mode of action of DNA injury in a mammal including a human, which comprises applying a cancer therapy based on the mode of action of DNA injury to a cancer patient, and administering a substance selected from a compound represented by the following general formula (I), a pharmacologically acceptable salt thereof, a hydrate

thereof, and a solvate thereof according to claim 1, at a dose sufficient to reduce the side effect of the cancer therapy.

23. (Withdrawn) The method according to claim 22, wherein R<sup>5</sup> is a phenyl group which may be substituted, a naphthyl group which may be substituted, a furyl group which may be substituted, a pyridyl group which may be substituted, or a benzimidazolyl group which may be substituted.

24. (Canceled)

25. (Currently Amended) The compound according to claim [[24]] 10, a pharmacologically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein A is a hydrogen atom, an acetyl group, or a para-toluenesulfonyl group.

26. (New) The medicament according to claim 1, wherein A is a hydrogen atom, an alkyl-carbonyl group, or an aryl-sulfonyl group which may be substituted with one or more alkyl groups.

27. (New) The medicament according to claim 1, wherein A is a hydrogen atom, an acetyl group, or a para-toluenesulfonyl group.

28. (New) The medicament according to claim 1, wherein R<sup>5</sup> is a phenyl group, 2,6-difluorophenyl group, 2,4-dichlorophenyl group, 3-nitrophenyl group, 4-nitrophenyl

group, 2-methylphenyl group, 4-(tert-butyl)phenyl group, 2-(trifluoromethyl)phenyl group, 4-(trifluoromethyl)phenyl group, 3,4-dihydroxyphenyl group, 2-methoxyphenyl group, 3-methoxyphenyl group, 2,3-dimethoxyphenyl group, 3,5-dimethoxyphenyl group, 3,4-methylenedioxyphenyl group, 3-aminophenyl group, 4-(dimethylamino)phenyl group, 4-methanesulfonylphenyl group, 1-naphthyl group, 5-methylfuran-2-yl group, pyridin-2-yl group, benzimidazol-2-yl group, or cyclohexyl group.

29. (New) The compound according to claim 10, a pharmacologically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein Z is a methylene group, an ethylene group, an ethane-1,1-diyl group, a propane-1,3-diyl group, a propane-1,2-diyl group, a propane-2,2-diyl group, or a butane-1,4-diyl group.

30. (New) The compound according to claim 10, a pharmacologically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein A is a hydrogen atom, an alkyl-carbonyl group, or an aryl-sulfonyl group which may be substituted with one or more alkyl groups.

31. (New) The compound according to claim 10, a pharmacologically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein R<sup>5</sup> is a phenyl group, 2,6-difluorophenyl group, 2,4-dichlorophenyl group, 3-nitrophenyl group, 4-nitrophenyl group, 2-methylphenyl group, 4-(tert-butyl)phenyl group, 2-(trifluoromethyl)phenyl group, 4-(trifluoromethyl)phenyl group, 3,4-dihydroxyphenyl group, 2-methoxyphenyl

group, 3-methoxyphenyl group, 2,3-dimethoxyphenyl group, 3,5-dimethoxyphenyl group, 3,4-methylenedioxyphenyl group, 3-aminophenyl group, 4-(dimethylamino)phenyl group, 4-methanesulfonylphenyl group, 1-naphthyl group, 5-methylfuran-2-yl group, pyridin-2-yl group, benzimidazol-2-yl group, or cyclohexyl group.

32. (New) The medicament according to claim 12, which is a specific inhibitor of a protein kinase and/or an analogous enzyme thereof.

33. (New) The medicament according to claim 12, which is used for reducing a side effect resulting from a cancer therapy based on a mode of action of DNA injury.